TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presentato ven 28 ago · 11:15 CESTHot Line 1Tutti gli studi Hot Line →

SINGLE-AF

2026

The Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Intermediate Stroke Risk in Patients With Atrial Fibrillation

In 1,803 patients with atrial fibrillation at intermediate stroke risk, a direct oral anticoagulant reduced the net composite of stroke, embolism, major bleeding and death at 2 years compared with no anticoagulation.

Risultato

Efficacia: Composite of stroke, systemic embolism, ISTH major bleeding and cardiovascular death at 2 yearsHR 0,31 (IC 95% 0,10-0,94) · P = 0,03

Sotto 1 a favore di a direct oral anticoagulant, sopra 1 a favore di no anticoagulation.

Tassi di eventi
Differenza assoluta
1,0 punti
NNT
100

La differenza assoluta e l’NNT sono derivati dai tassi di eventi.

Riportato inoltre: Driven by ischaemic stroke (0.1% vs 1.1%). Major bleeding 0.3% vs 0.5%.

Pubblicazione originale
Sottotema
Stroke prevention
Disegno
Investigator-initiated, multicentre, open-label, superiority RCT with blinded outcome adjudication (PROBE), 1:1, permuted blocks stratified by centre, 24-month follow-up, South Korea
Rilevanza
Importante: uno dei diversi pilastri.
Fonte
Kim D, Lee Y, et al. N Engl J Med. 2026; published online 28 August.doi 10.1056/nejmoa2607978

Discussione e critica

The first randomised answer for atrial fibrillation with a single stroke risk factor, and it favours anticoagulating. Fewer than 20 primary events across 1,803 patients carry the result: the interval runs to 0.94, so the direction is firmer than the size. Open-label at 18 Korean centres, with an observed event rate far below the planning assumption and an absolute difference of one percentage point.

Discusso nei podcast